Evaluation of <i>Helicobacter pylori</i> stool antigen test before and after eradication therapy

Tanaka, Akifumi; Watanabe, Kazuhiro; Tokunaga, Kazutoshi; Hoshiya, Satoshi; Imase, Kiyoto; Sugano, Hajime; Shingaki, Masao; Kai, Akemi; Itoh, Takeshi; Ishida, Hideyuki; Takahashi, Shinichi

doi:10.1046/j.1440-1746.2003.03057.x

Cited by 18 publications

(17 citation statements)

References 28 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reason is unclear; however, identification of H. pylori coccoid forms was possible by the immunoassay but not by UBT. The usefulness of the polyclonal stool antigen test has been reported in the Japanese population undergoing eradication therapy [9][10][11]. In the present study, we showed the clinical usefulness of the stool antigen test using monoclonal antibody to evaluate eradication therapy in Japanese patients.…”

Section: Discussionsupporting

confidence: 57%

Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 57%

Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The HpSA test has been widely evaluated around the world, with a weighted mean sensitivity and specificity of 90-98%, respectively [13,15,16] . The HpSA test is a cheap and useful method for the diagnosis of H pylori infection before and after eradication therapy [17,18] . It is an accurate test in all age groups of children too [19] .…”

Section: Discussionmentioning

confidence: 99%

Clinical value ofHelicobacter pyloristool antigen test, ImmunoCard STAT HpSA, for detectingH pyloriinfection

Li¹,

Guo²,

Zhang³

et al. 2004

WJG

View full text Add to dashboard Cite

“…15 At least 4 weeks after the end of eradication therapy, successful eradication was confirmed using UBT or HpSA. [16][17][18] The cut-off value for a negative UBT was <2.5%. 16 Values of UBT between 2.5 and 5.0% were considered as being in the gray zone.…”

Section: Methodsmentioning

confidence: 99%

Current status of first- and second-lineHelicobacter pylorieradication therapy in the metropolitan area: a multicenter study with a large number of patients

Mori

Suzuki

Omata

et al. 2019

Therap Adv Gastroenterol

Self Cite

View full text Add to dashboard Cite

Background: The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan’s demographic structure is becoming pronounced. In this study, we examined the trend of the eradication rate of H. pylori in the metropolitan area and examined factors concerning successful eradication. Methods: We collected data from 20 hospitals in the Tokyo metropolitan area on patients who received first-line eradication therapy with a proton-pump inhibitor (PPI)/P-CAB, amoxicillin, and clarithromycin for 1 week and second-line eradication therapy with a PPI/P-CAB, amoxicillin, and metronidazole for 1 week from 2013 to 2018. The annual eradication rate and associated factors for successful eradication were analyzed. Results: We collected data of 4097 and 3572 patients in the first- and second-line eradication therapies, respectively. The eradication rate decreased from 2013 to 2014 and increased again from 2015 to 2018 with the first-line therapy [the eradication rates in 2013, 2014, 2015, 2016, 2017 and 2018 were 71.8%, 63.7%, 78.5%, 84.6%, 89.7 and 90.1%, respectively, in the per protocol (PP)]. The second-line eradication rates were 90.0%, 82.6%, 88.8%, 87.5%, 91.8% and 90.1% in 2013, 2014, 2015, 2016, 2017 and 2018, respectively, in PP. Vonoprazan was an independent factor for successful eradication in not only first-line, but also second-line eradication. Age over 75 years was an independent factor for eradication failure in both first- and second-line eradication therapies. Conclusion: The eradication rate improved from 2015 to 2018 with the first-line therapy because of the introduction of vonoprazan in the market. The eradication rates with first- and second-line regimens in elderly patients were lower than those in younger patients.

show abstract

Evaluation of Helicobacter pylori stool antigen test before and after eradication therapy

Abstract: The HpSA test is a useful method for the diagnosis of H. pylori infection before and after eradication therapy.

Cited by 18 publications

References 28 publications

Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy

Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy

Clinical value ofHelicobacter pyloristool antigen test, ImmunoCard STAT HpSA, for detectingH pyloriinfection

Current status of first- and second-lineHelicobacter pylorieradication therapy in the metropolitan area: a multicenter study with a large number of patients

Contact Info

Product

Resources

About